Therapeutics Stock Surges 40% After Favorable Clinical Trial Results

4D Molecular Therapeutics Soars In Premarket After Impressive Phase 2 Clinical Trial Results.

Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.

In a surprising turn of events, shares of 4D Molecular Therapeutics (NASDAQ: FDMT) surged over 40% to $24.99 in premarket trading following the release of interim data from their randomized Phase 2 PRISM clini…